10/20/2026
𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀: 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗟𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝗶𝗲𝘀 𝗖𝗮𝗽𝗮𝗯𝗹𝗲 𝗼𝗳 𝗣𝗲𝗿𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗢𝘅𝗳𝗼𝗿𝗱 𝗡𝗮𝗻𝗼𝗽𝗼𝗿𝗲 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 (𝗢𝗡𝗧) 𝗟𝗼𝗻𝗴-𝗥𝗲𝗮𝗱 𝗪𝗵𝗼𝗹𝗲 𝗚𝗲𝗻𝗼𝗺𝗲 𝗦𝗲𝗾𝘂𝗲𝗻𝗰𝗶𝗻𝗴
RISE (Rare Insights, Solutions, Empowerment) is a global initiative of Genetic Alliance that works to eliminate barriers to genomic testing by expanding access to clinical-grade genomic sequencing and other high-impact genomic diagnostics for patients with suspected pediatric-onset rare genetic diseases. RISE focuses on individuals from low- and middle-income countries (LMICs) and communities.
Through this Request for Applications (RFA), Genetic Alliance seeks to identify clinical laboratories capable of performing long-read whole genome sequencing (lrWGS) using Oxford Nanopore Technologies platforms. Selected laboratories will receive support to expand access to testing for underserved populations using ONT-based genomic sequencing.
In return, participating laboratories will commit to providing no-cost, clinical-grade genomic testing for undiagnosed patients referred through the RISE clinical network.
This partnership will help expand access to genomic diagnostics for underserved populations while contributing to a global effort to diagnose children with rare genetic diseases and improve clinical care.
𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝗻𝘁 𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝗶𝗲𝘀 𝗺𝘂𝘀𝘁 𝗺𝗲𝗲𝘁 𝘁𝗵𝗲 𝗳𝗼𝗹𝗹𝗼𝘄𝗶𝗻𝗴 𝗰𝗿𝗶𝘁𝗲𝗿𝗶𝗮:
1. Provide clinical-grade genomic testing using ONT sequencing workflows; or be in the process of establishing clinical-grade genomic testing using ONT sequencing workflows, with a defined implementation plan and timeline.
2. Hold accreditation or certification from a recognized regulatory or quality standards body (e.g., CLIA, CAP, ISO 15189, or relevant national equivalents).
3. Offer clinician-ordered testing that includes, at minimum, detection and interpretation of single nucleotide variants (SNVs), small insertions and deletions (indels), and copy number variants (CNVs), with interpretation of potentially disease-causing variants and delivery of a clinical diagnostic report.
4. Be able to support associated operational costs if RISE provides sequencing reagents, sample preparation materials, cloud storage, and/or analysis software to enable testing for patients from participating clinical sites.
5. Demonstrate capacity to support testing volumes of at least 50 trios per year.
6. Agree to provide no-cost genomic testing for patients and families referred through the established RISE clinical site network.
𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗧𝗶𝗺𝗲𝗹𝗶𝗻𝗲
- 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗼𝗽𝗲𝗻𝘀: October 16, 2026
- 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗰𝗹𝗼𝘀𝗲𝘀: October 30, 2026
- 𝗦𝗲𝗹𝗲𝗰𝘁𝗶𝗼𝗻 𝗶𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄𝘀: November 2–13, 2026
- 𝗔𝘄𝗮𝗿𝗱 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗱: December 1, 2026
𝗔𝗽𝗽𝗹𝘆 𝗵𝗲𝗿𝗲:
This link will take you to a page that’s not on LinkedIn